Outcomes of endovascular treatment for aortic pseudoaneurysm in Behcet's disease  by Kim, Sung Won et al.
From
Sc
an
va
M
Supp
C
Auth
Rep
of
of
R
The
to
m
0741
Cop
http
608Outcomes of endovascular treatment for aortic
pseudoaneurysm in Behcet’s disease
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Young Nam Yoon, MD,b Donghoon Choi, MD,c and Young-Guk Ko, MD,c Seoul, Republic of Korea
Objective: To evaluate the effectiveness of endovascular stent grafting for surgical management of aortic pseudoaneurysm
in patients with Behcet’s disease (BD).
Methods:We present a single-institution retrospective cohort of patients with aortic pseudoaneurysm and BD treated with
aortic stent grafting. Computed tomography imaging was obtained preoperatively in all patients and once within 2 weeks
postoperatively, and then annually. Clinical follow-up and erythrocyte sedimentation rate were used to follow BD activity.
Immunosuppressant therapy was instituted prior to endovascular treatment unless a contraindication existed.
Results: From 1998 to 2012, 10 patients (eight male, two female; median age, 39) with BD and aortic pseudoaneurysm
were treated with endovascular stent grafting at this institution. Ninety percent of these patients received immunosup-
pressive therapy before and after surgical treatment. The median follow-up period was 57 months (interquartile range,
43-72). The locations of the 12 pseudoaneurysms treated in this cohort were infrarenal abdominal aorta (seven),
descending thoracic aorta (four), and aortic arch (one). Median pseudoaneurysm size was 4.5 cm (interquartile range,
3.4-5.9). At long-term follow-up, complete resolution of the aortic pseudoaneurysm was noted in all patients. No
endoleaks occurred. Newly developed pseudoaneurysm at the distal margin of the stent graft was noted in one patient
17 months after the stent graft procedure. One patient required a subsequent stent graft placement for an expanding
pseudoaneurysm of the subclavian artery. No patient deaths occurred during the follow-up period.
Conclusions: Endovascular treatment of aortic pseudoaneurysm with stent-grafting in patients with BD is safe and
effective with long-term durability. (J Vasc Surg 2014;59:608-14.)Behcet’s disease (BD) is a multisystem chronic in-
ﬂammatory condition with neurologic, cardiovascular,
pulmonary, and musculoskeletal manifestations. Vascular
involvement, termed vasculo-BD, has been reported to
occur in 7% to 29% of affected patients.1 In vasculo-
BD, both veins and arteries may be affected. Venous
lesions range from superﬁcial thrombophlebitis to occlu-
sive lesions of the vena cava, and stenosis and/or pseudo-
aneurysms may occur in the peripheral arteries and the
aorta. Venous thrombosis is the most frequent vascular
complication of this disease, but pseudoaneurysm and
rupture of the large arteries or the aorta, while less
frequent, are of greater concern, since these events are
a major cause of mortality in this condition.2
In the surgical treatment of vasculo-BD, anastamotic
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://dx.doi.org/10.1016/j.jvs.2013.09.052Pseudoaneurysms of anastomotic sites may occur in 30% to
50% of them.3 At the time of reoperation in the setting of
an anastomotic dehiscence, arterial reconstruction may be
difﬁcult to achieve. In an effort to reduce complications,
endovascular treatment has been proposed as an alternative
to open surgery in BD. Several studies have reported success-
ful treatment of abdominal aortic pseudoaneurysm with the
use of endovascular stent grafts in BD.4-7 However, there exist
few reports describing the long-term outcomes of endovascu-
lar treatment for pseudoaneurysm in these patients. The
purpose of this study was to investigate the long-term effec-
tiveness and safety of endovascular treatment for aortic
pseudoaneurysm in patients with BD.METHODS
Clinical database and patient characteristics. This
study was approved by the Institutional Review Board.
To identify subjects for enrollment in this retrospective
series, records from all patients who underwent endovascu-
lar stent graft aortic pseudoaneurysm repair at this institu-
tion between 1998 and 2012 were reviewed to ﬁnd
patients with a coexistent diagnosis of BD. With regard
to diagnosis, all patients satisﬁed the International Study
Group Criteria for BD, which requires the presence of
oral ulceration plus any two of genital ulceration, typical
deﬁned eye lesions, typical deﬁned skin lesions, or a positive
pathergy test.8 All the patients had taken negative results
for the blood culture to rule out mycotic aneurysm. The
ﬁnal study cohort consisted of 10 patients.
Stent graft technical description. All patients under-
went preprocedure computed tomography (CT) imaging
Table I. Patient characteristics
Patient Gender Age
Anatomic
distribution
Max. diameter
of aneurysm,
mm
Elapsed time
from initial
diagnosis,
months
Combined arterial
involvement Previous operation history
1 M 38 AA 25 90 None Bypass graft due to aortic
dissectiona
2 M 39 AA 45 50 Right SFA pseudoaneurysm,
left popliteal artery
occlusion
Graft replacement from left
CFA to right SFA due to
left iliac artery occlusion
3 M 52 AA 45 154 None None
4 M 35 AA 141 0 Right CFA pseudoaneurysm,
right SCA pseudoaneurysm
None
5 M 44 AA 104 134 Right popliteal artery
occlusion, segmental
occlusion of right SFA
Left total hip replacement
and right hip bone graft
due to bilateral AVN
6 M 52 AA 33 69 None None
7 M 49 AA 45 173 None None
8 F 38 DT (multiple) 63 92 None None
9 M 36 DT 27 2 Left SCA aneurysm None
10 F 38 Aortic arch
(including left
SCA oriﬁce)
36 21 Left SCA occlusion None
AA, Infrarenal abdominal aortic; AVN, avascular necrosis; CFA, common femoral artery; DT, descending thoracic; SCA, subclavian artery; SFA, superﬁcial
femoral artery.
aGraft-interposition surgery (from infrarenal aorta to aortic bifurcation) for aortic dissection.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 3 Kim et al 609to guide the individual selection of a stent graft implant.
The diameter of the stent graft used was chosen to be
10% to 15% larger than the diameter of the aorta measured
on CT. We placed the stent graft with at least 2 cm safety
margin of healthy aorta. However, a healthy aortic wall
cannot be easily differentiated from the BD-involved
segment of aorta in many cases. For these, we placed the
stent graft as long as possible to cover the possible BD
involved segment. In this series, the implants selected
consisted of self-expandable SEAL stent-grafts (S&G
Biotech, Gyeonggi-do, South Korea), Excluder stent-graft
(W. L. Gore & Associates, Flagstaff, Ariz), and custom-
designed Z-type stent-graft (Tae Woong Medical, Seoul,
South Korea). Deployed stent-grafts were subsequently
dilated with an Equalizer occlusion balloon catheter
(Boston Scientiﬁc, Natick, Mass) with 10% to 20% oversize.
Percutaneous access (n ¼ 9) or cut-down technique
(n ¼ 1) was obtained through either the right or bilateral
common femoral arteries, and each stent graft was inserted
through the opening of the arterial puncture site. Technical
success of the procedure was deﬁned as complete exclusion
of the inlet of the saccular pseudoaneurysm from the circu-
lation and the absence of perigraft leakage on aortography.
Medical management. Immunosuppressive therapy
was administered before and after surgical intervention.
The dose of prednisolone (Yuhan, Seoul, South Korea)
was adjusted between 5 and 60 mg/day, according to
each patient’s clinical condition, and azathioprine (50-
100 mg/day; Myungmoon Pharm, Seoul, South Korea)
and/or colchicines (1.2 mg/day; Korea United Pharm,
Seoul, South Korea) were added if needed according to
clinical condition and disease activity. Each patient’simmunosuppressive regimen was adjusted based on serial
measurement of the erythrocyte sedimentation rate (ESR)
using the Westergren method (Espette, Korea; reference
range <20 mm/h).
Follow-up evaluation. Follow-up clinical evaluation
and CT imaging was obtained preoperatively in all patients
and once within two weeks postoperatively, and then annu-
ally. CT images were reviewed for stent graft placement,
diameter of the aorta, complete obliteration and throm-
bosis of the pseudoaneurysm sac, and the occurrence of
complications, speciﬁcally pseudoaneurysm.
Statistical analysis. Quantitative variables were
expressed as median and interquartile range, and qualitative
variables were expressed as absolute and relative frequen-
cies. The Wilcoxon matched-pairs signed-rank test (two-
tailed probability) was used for intergroup comparisons. A
P value of less than 0.05 was chosen as the threshold for
indicating a statistically signiﬁcant difference. Statistical
analysis was performed with SPSS software (version 17.0;
SPSS, Chicago, Ill).
RESULTS
The ﬁnal study cohort consisted of 10 patients (eight
men, two women; median age, 39 years [interquartile
range (IQR), 38-48 months]). Patient demographics are
given in Table I. In this cohort, aortic pseudoaneurysm
was detected a median of 80 months (IQR, 28-
124 months) after the initial diagnosis of BD. In these
10 patients, 12 pseudoaneurysms were identiﬁed, and all
were saccular pseudoaneurysms: seven in the infrarenal
abdominal aorta (Fig 1), four in the descending thoracic
aorta, and one in the aortic arch. One patient had multiple
Fig 1. A 35-year-old male with ruptured abdominal aortic aneu-
rysm. A, Axial image demonstrates a ruptured aortic aneurysm and
subsequent retroperitoneal hemorrhage (arrows). B, Abdominal
aortogram following stent graft placement demonstrates that the
aneurysm has almost disappeared. C, At the 52-month follow-up,
three-dimensional volume rendering computed tomography (CT)
image reveals the aneurysm has completely regressed.
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pseudoaneurysms located in the descending thoracic aorta
(Fig 2). Five patients (50%) had other associated arterial
pathologies, including pseudoaneurysm and/or occlusion
of the femoral, popliteal, or subclavian arteries.
Technical success was achieved in all patients with no
immediate complications from the stent graft procedures.
One patient required additional endovascular procedures
for the treatment of arterial pseudoaneurysms of the right
common femoral artery and the right subclavian artery,
10 days after the initial treatment of the patient’s abdom-
inal aortic lesion.
Clinical follow-up. Median follow-up duration was
57 months (IQR, 43-72 months). Imaging studies
revealed complete resolution of the aortic pseudoaneur-
ysms in all patients, and the median diameter of the aorta
was signiﬁcantly reduced from 4.5 cm (IQR, 3.4-5.9 cm)
to 2.3 cm (IQR, 2.1-2.5 cm; P ¼ .005). No patients
experienced complications from the initial procedure
requiring reintervention. In one patient treated for an
abdominal aortic pseudoaneurysm, a new pseudoaneurysm
developed at the distal margin of the stent graft that was
diagnosed 17 months after the ﬁrst procedure. This new
lesion was followed by serial imaging for 5 years. This
pseudoaneurysm was noted to slowly increase in size over
the course of the ﬁrst 3 years following its identiﬁcation, up
to a diameter of 28 mm, but its size has been stable in the
subsequent 2 years leading up to the time of this report, so
no further intervention has yet been performed.
During the follow-up, one patient, who had initially
been treated for a pseudoaneurysm in the descending
thoracic aorta, required further treatment for an arterial
pseudoaneurysm of the left subclavian artery that had
expanded to 6.4 cm. This was treated with a hybrid endo-
vascular procedure, in which “right common carotid artery
to left common carotid artery bypass grafting with ligation
of left common carotid and left subclavian artery” was per-
formed ﬁrst, followed by a stent graft insertion from the
aortic arch to the descending thoracic aorta. This pseudo-
aneurysm resolved following this procedure in 13 months
of subsequent follow-up.
Nine (90%) patients in this cohort received immuno-
suppressive therapy at the time of their endovascular
procedure and continued this treatment during follow-
up. The one patient not on immunosuppressive therapy
had previously received steroid therapy for 3 years and
had developed bilateral femoral head avascular necrosis
(AVN). Steroid therapy was considered to be contraindi-
cated in this individual. At the time of endovascular treat-
ment, six patients had ESR values in the normal range,
and four patients demonstrated persistently elevated
ESR values.
For all patients except the individual who had been
diagnosed with AVN, immunosuppressive medications
were continued during the follow-up period, with medica-
tion doses adjusted based on disease activity as measured by
ESR. Three patients were noted on follow-up to have ESR
elevations. One of these patients was the patient with AVN,
Fig 2. A 38-year-old female with multiple descending thoracic aortic aneurysms. A, Axial image reveals thoracic aortic
pseudoaneurysm (white arrows). B, Aortogram demonstrates that the aneurysm is no longer visualized after stent graft
placement. C, The aneurysm in the descending thoracic aorta has completely regressed after 70 months.
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endovascular intervention and who has not demonstrated
any recurrence or complications after 52 months of
follow-up. In the second patient with an elevated ESR,
during the follow-up, the patient had stopped medication
several times of his own will and skipped periodic outpa-
tient visiting. So appropriate dose control was not possible,
and he was noted to have large ﬂuctuations of his ESR
(36 6 30 mm/h [mean 6 standard deviation]) during
follow-up. At 17-month follow-up, he was found to have
a new aortic pseudoaneurysm that developed at the distal
margin of the stent graft. The third patient in elevated
ESR had been in low compliance with medication but,
with the increase of her compliance, ESR level was nearly
normalized. On follow-up, her pseudoaneurysm has
completely resolved.DISCUSSION
Aortic pseudoaneurysm is a rare complication of BD,
but this complication is associated with high morbidityand mortality if rupture occurs. Outcomes of endovascular
or surgical treatment have been described (Table II).
Surgical treatment of aortic pseudoaneurysm in the setting
of BD has been frequently reported to be unsuccessful,
with high rates of occlusion and postoperative anastomotic
pseudoaneurysm. Ozeren et al9 reported that following 12
primary operations for arterial occlusion or aneurysm in
BD, 12 reoperations on seven patients were required due
to complications including graft thrombosis, bleeding,
graft infection, aortoenteric ﬁstula, and anastomotic pseu-
doaneurysm. Similarly, Liu et al10 reported the results of
a meta-analysis that found that pseudoaneurysm-related
mortality with surgery was 10% to 30%, and that recurrent
pseudoaneurysm developed at an anastomotic site in 10%
to 50% of patients with BD. The shared conclusion of these
authors was that surgical treatment of arterial complica-
tions in BD was unsatisfactory. Since the ﬁrst successful
outcome of endovascular stent grafting by Vasseur et al,4
many investigators have reported endovascular procedures
are effective in reducing postoperative complications
compared with open surgical treatments.11-14 One criticism
Table II. Recent studies concerning Behcet’s disease (BD) in vascular patients
First
author Year
Case,
No. Involvement Vascular symptom
Preoperative
medication
Ozeren9 2000 12 Arterial aneurysm or occlusion Abdominal pain, pain in
extremities, pre-shock
CS, CCC
Park12 2001 7 Aortic or arterial aneurysm NA NA
Koo14 2003 9 Arterial pseudoaneurysm NA ST, AZA
Iscan21 2005 20 Arterial aneursym (19), occlusion (1) Visceral pain, abdominal pain NA
Kalko15 2005 16 Arterial aneurysm NA ST, CPM
Hosaka22 2005 10 Arterial aneurysm NA ST, CCC
Ohshima23 2008 1 CCA aneurysm Swelling, pulsatile mass NA
Kwon16 2008 12 Abdominal aortic pseudoaneurysm NA ST, AZA, CCC, CPM
Liu10 2009 10 Arterial pseudoaneurysm Abdominal pain, back pain ST, CPM
Kim17 2009 16 Arterial pseudoaneurysm NA ST, AZA, CCC
2009 7 Arterial pseudoaneurysm NA NA
Saadoun24 2012 101 Arterial aneurysms, occlusions, stenosis,
aortitis
NA ST (86.1%), IMM (CPM,
AZA) (78.2%)
Tuzun25 2012 25 Nonpulmonary arterial aneurysm (23),
occlusion (2)
NA ST, CPM
Unal26 2013 11 Arterial pseudoaneurysm (responsed to
medication)
NA IMM
AZA, Azathioprine; CCC, colchicines; CPM, cyclophosphamide; CS, cyclosporine; EV, endovascular intervention; IMM, immunosuppressant; NA, not
available; SG, surgery; ST, corticosteroids.
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follow-up reported for endovascular treatments in BD
prevents a fair comparison with outcomes for open surgical
procedures.15 In support of this concern, Kwon et al16 re-
ported a relatively high rate of recurrent pseudoaneurysm
at the margins of endovascular stent grafts in a patient
cohort with a mean follow-up duration of 45.5 months.
However, their work only describes stent grafting on four
patients, which is too small of a sample size to have a statis-
tically meaningful discussion. Additionally, three of those
four cases were follow-up treatments for pseudoaneurysms
caused by a previous interposition surgery or a patchy-
closure surgery, which cannot be strictly considered as
complication of stent grafting. In contrast, Kim et al17
have reported follow-up results of stent grafting of 20 arte-
rial aneurysms in 16 BD patients. In this case series with
a mean follow-up duration of 47.6 months, only three
patients were found to have complications. It should be
noted, though, that this study included a heterogeneous
group of lesions affecting vessels ranging in size from small
arteries to the aorta.
While BD may affect vessels of a range of sizes, involve-
ment of the large arteries or aorta particularly places the
patient at risk for signiﬁcant morbidity and mortality. As
for follow-up duration, a prolonged monitoring is required
in vascular BD patients, since recurrence of pseudoaneur-
ysm at the site of surgery is possible. In this study, we inves-
tigated long-term outcomes of endovascular stent graft
treatment for aortic pseudoaneurysm in patients with BD.
We conclude from our results that endovascular treatment
of aortic pseudoaneurysm in BD patients is safe and effec-
tive based on our data and long-term follow-up results. In
this study, all aortic pseudoaneurysms were completely
resolved at a median follow-up duration of 57 months.In a cohort of 10 patients, only one patient (10%) devel-
oped a new pseudoaneurysm at the distal margin of the
stent graft, and this newly developed pseudoaneurysm has
been stable in size on follow-up for the last 2 years. Our
complication rate (10%) is lower than the previously pub-
lished rates of postoperative pseudoaneurysm for open
surgical interposition, which are reportedly between 30%
and 50%,3,18 and lower than the published rates of postop-
erative pseudoaneurysm occurring after endovascular inter-
vention, which range from 14.3% to 22.2%.10,12,14
In the treatment of arterial pseudoaneurysm in
BD, endovascular interventions have also been found to
have higher survival rates compared with open proce-
dures.10,12,14 In this study, all patients survived until the
time of last follow-up. In addition, no primary lesions
have required reintervention following stent grafting.
Another aspect of the surgical management of BD that
has received recent attention is the use of immunosuppres-
sive agents.9 Ando et al19 have proposed that steroids
should be given to BD patients pre- and postoperatively
in order to modulate inﬂammation and thereby reduce
complications. This practice is supported by the results of
Koo et al14 and Liu et al,10 who reported, although with
a small number of patients, that patients without taking
immunosuppressant had a higher recurrence rate.
The standard immunosuppressive regimen for BD is
steroid, and optionally azathioprine and colchicines can
be used.18 In this study, patients were prescribed predniso-
lone and optionally colchicines and azathioprine before and
after their procedures according to each patient’s clinical
condition and ESR values to measure BD activity.20
Although endovascular procedures are less invasive
than open surgery, stents and/or stent grafts may provoke
inﬂammation within the aortic wall by foreign body
Surgery,
No. (%)
Endovascular,
No. (%)
Intervention-related
death, No. (%)
Recurred pseudoaneurysm,
No. (%)
Occlusion,
No. (%) Follow-up, mean
12 (100) None 0 (0) 3 (25) 3 (25) 36 months
none 7 (100) 0 (0) 1 (14) 1 (14) 28 months
none 9 (100) 0 (0) 1 (11) 1 (11) 24.1 months
20 (100) None 2 (10) 10 (50) 9 (45) 44 months
16 (100) None 0 (0) 2 (13) NA 17 months
10 (100) None 1 (10) 5 lesions (10) 5 lesions (24) 133 months
None 1 (100) 0 (0) 0 (0) 0 (0) 12 months
11 (92) 4 (33) 0 (0) SG: 5 (45),
EV: 2 (50)
NA 45.5 months
None 10 (100) 0 (0) 2 (20) NA 25.8 months
None 16 (100) 0 (0) 2 (13) 2 (13) 47.6 months
7 (100) None 1 (14) 2 (29) NA NA
47 (47) 1 (1) NA NA 9 (19) 7.6 years
22 (88) None 1 (5) 2 (9) 10 lesions (40) 7.4 years
None None NA 6 (55) NA 20 months
Table II. Continued.
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to the recurrence of pseudoaneurysm after endovascular
treatments, especially at the both margins of the stent.
Thus, immunosuppressive therapy may reduce the risk of
these complications by decreasing and modulating these
inﬂammatory reactions. Not only was the postprocedural
medication important, but also the preprocedural remission
of the disease activity. The establishment of the remission
before the surgical intervention decreases the incidence of
postoperative complications as suggested by Kalko et al15
In terms of establishment of remission of BD before the
surgical treatment, we have experienced only four graft
replacement surgeries for aortic pseudoaneurysms in BD
patients. Three patients achieved normal range of ESR level
before surgery, whereas one patient with elevated ESR pre-
sented as ruptured aortic pseudoaneurysm and expired
during emergent surgery. Among three patients who
survived, one patient was lost to follow-up. The remaining
two patients had no complication or recurred pseudoa-
neurysm until the follow-up, 57 and 47 months, respec-
tively. Thus, we believe that ESR levels are important
during pre- and postoperative periods, but further large
study should be mandatory.
In this study, we tried to normalize every patient’s ESR
to achieve BD remission prior to the endovascular proce-
dure. However, four patients still had elevated ESR at
the time of the endovascular procedure, and we could
not wait for the remission to occur. Speciﬁcally, the ﬁrst
two already had ruptured pseudoaneurysm, the third
patient could not use corticosteroids due to his bilateral
femoral head AVN, and the last one showed an aggravation
of abdominal pain.
Immunosuppressant therapy was continued following
endovascular treatment and serial ESR values were obtainedfor all patients at follow-up evaluations. At follow-up, three
patientswere noted tohave elevatedESR levels despite being
on immunosuppressant medication, and as discussed in the
results section above, the one patient who developed a new
pseudoaneurysm at the distal margin of his stent graft was
noted to have an elevated ESR (preprocedure ESR,
23 mm/h; mean postprocedure ESR, 36 mm/h). Further
studies are needed to establish if ESR elevation is associated
with a greater risk of pseudoaneurysm recurrence, and if
more aggressive immunosuppression is effective in prevent-
ing this complication.
In this study, a more sophisticated data analysis such
as a multivariate analysis was not possible due to the small
sample size of the dataset. We aim to initiate a multi-center
study to collect a larger number of samples for this rare
disease as future work. Also, we are considering a possible
extension to this study such as analyzing any association
between BD and hyperhomocysteinemia and/or inte-
grating statin therapy data.
CONCLUSIONS
In summary,weconclude that endovascular stentgrafting
for aortic pseudoaneurysm inBD is safe and effective on long-
term follow-up.We suggest that BDactivity should bemodu-
lated before and after the procedure with the use of immuno-
suppressive therapy. Further investigations are needed to
determine the speciﬁc dosing and duration of immunosup-
pressant therapy that is most effective for the prevention of
recurrence of aortic pseudoaneurysm in these cases.
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